Fri, 01 Aug 2014 21:42:12 GMT View Comments

Recent drug approvals at Sunovion to make up for Lunesta patent expiry

Surveyed u.s. psychiatrists would prescribe otsuka/lundbeck's brexpiprazole to 12 percent of their treatment-resistant depression patients, However, responses from surveyed managed care organization directors suggest that newer-to-market agents forest laboratories/pierre fabre's fetzima, takeda/lundbeck's brintellix and dainippon sumitomo/sunovion's latuda are in danger of remaining excluded.

White belly dancers are racist, complains salon writer, Any attempt to overcome racism is probably doomed when the opposite of racism - the positive embrace of other races and their culture - is also considered racist. this hopelessness is on full display in an article for salon by novelist randa jarrar, who.

Studies demonstrate effective weight loss strategies, Prior to the publication of these studies, there has been a lack of scientific evidence for the vast majority of commercial weight loss programs. in the first study, bret h. goodpaster, ph.d., from the university of pittsburgh school of medicine and.

Related Headline News and Top Stories

OpportunityAnalyzer: Autism Spectrum Disorder - Opportunity Analysis and Forecasts to 2018

Post Date: Tue, 18 Mar 2014 10:43:00 GMT by

Opportunityanalyzer: autism spectrum disorder - opportunity analysis and forecasts to 2018 - Summary autism spectrum disorders (asd) is a chronically underserved market currently dominated by the two approved drugs, both of which are antipsychotics. there is off-label use of a multitude of other drugs which target different core and non-core.

Visit source OpportunityAnalyzer: Autism Spectrum Disorder - Opportunity Analysis and Forecasts to 2018

SURVEYED U.S. PSYCHIATRISTS WOULD PRESCRIBE OTSUKA/LUNDBECK'S BREXPIPRAZOLE TO 12 PERCENT OF THEIR TREATMENT-RESISTANT DEPRESSION PATIENTS

Post Date: Mon, 23 Jun 2014 10:48:00 GMT by

Surveyed u.s. psychiatrists would prescribe otsuka/lundbeck's brexpiprazole to 12 percent of their treatment-resistant depression patients - However, responses from surveyed managed care organization directors suggest that newer-to-market agents forest laboratories/pierre fabre's fetzima, takeda/lundbeck's brintellix and dainippon sumitomo/sunovion's latuda are in danger of remaining excluded.

Visit source SURVEYED U.S. PSYCHIATRISTS WOULD PRESCRIBE OTSUKA/LUNDBECK'S BREXPIPRAZOLE TO 12 PERCENT OF THEIR TREATMENT-RESISTANT DEPRESSION PATIENTS

White Belly Dancers are Racist, Complains Salon Writer

Post Date: Sat, 08 Mar 2014 23:12:00 GMT by

White belly dancers are racist, complains salon writer - Any attempt to overcome racism is probably doomed when the opposite of racism - the positive embrace of other races and their culture - is also considered racist. this hopelessness is on full display in an article for salon by novelist randa jarrar, who.

Visit source White Belly Dancers are Racist, Complains Salon Writer

Studies Demonstrate Effective Weight Loss Strategies

Post Date: Thu, 21 Oct 2010 17:00:00 GMT by

Studies demonstrate effective weight loss strategies - Prior to the publication of these studies, there has been a lack of scientific evidence for the vast majority of commercial weight loss programs. in the first study, bret h. goodpaster, ph.d., from the university of pittsburgh school of medicine and.

Visit source Studies Demonstrate Effective Weight Loss Strategies

PM360 Announces 2014 Trailblazer Award Finalists

Post Date: Wed, 20 Aug 2014 06:10:00 GMT by

Pm360 announces 2014 trailblazer award finalists - The finalists are in for the sixth-annual pm360 trailblazer awards. pm360, a leading health-marketing industry trade magazine, will honor the pharmaceutical industry's most influential innovators. established in 2009, the trailblazer awards are given to.

Visit source PM360 Announces 2014 Trailblazer Award Finalists

Surveyed U.S. Psychiatrists Would Prescribe Otsuka/Lundbeck's Brexpiprazole to 12 Percent of Their Treatment-Resistant Depression Patients

Post Date: Mon, 23 Jun 2014 10:12:00 GMT by

Surveyed u.s. psychiatrists would prescribe otsuka/lundbeck's brexpiprazole to 12 percent of their treatment-resistant depression patients - Burlington, mass., june 23, 2014 /prnewswire/ -- decision resources group finds that surveyed u.s. psychiatrists are receptive to novel adjunctive therapies to antidepressants for treatment-resistant depression (trd) and would prescribe otsuka/lundbeck's.

Visit source Surveyed U.S. Psychiatrists Would Prescribe Otsuka/Lundbeck's Brexpiprazole to 12 Percent of Their Treatment-Resistant Depression Patients